Trial reportWiener klinische Wochenschrift2008
[Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: the Austrian Hospital Screening Project (HSP)].
Trial report in Wiener klinische Wochenschrift, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- PCSK9 inhibitors in real life-Cardiometabolic risk management in dyslipidemic patients in Vienna.Wiener klinische Wochenschrift · 2025Article
- Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.Wiener klinische Wochenschrift · 2022Observational
- Are there differences in LDL-C target value attainment in Austrian federal states? Yes!Wiener medizinische Wochenschrift (1946) · 2013Observational
- Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS).Wiener klinische Wochenschrift · 2011Article
- [LDL-cholesterol in secondary prevention: goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL)].Wiener klinische Wochenschrift · 2011Article
- Review
- Long-term impact of a structured group-based inpatient-education program for intensive insulin therapy in patients with diabetes mellitus.Wiener klinische Wochenschrift · 2010Article
- Biosynthesis of isoprenoids via the non-mevalonate pathway.Cellular and molecular life sciences : CMLS · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is the major cause of morbidity and premature death in most European populations. Due to its prominent role as a risk factor for cardiovascular mortality, lowering of low density lipoprotein cholesterol (LDL-C) levels is the main goal for management of dyslipidemia. To evaluate lipid profiles and management of high risk patients with hyperlipidemia, we performed an observational study in 20 Austrian Departments of Medicine specialized in cardiology, diabetes and/or metabolism from July 2006 to February 2007. Out of 9152 patients [age (mean +/- SD): women 69 +/- 13, men 65 +/- 12 years) 6838 were considered at "very high risk" (group 1; LDL-C: 99 +/- 38 mg/dl) and 2314 at "high risk" (group 2; LDL-C: 108 +/- 39 mg/dl), respectively. Of 4886 patients on statins, 48% of did not reach their LDL-C goals (<70 mg/dl and <100 mg/dl for group 1 and 2, respectively). In 68% of these patients statin therapy was not intensified subsequently. Among patients without lipid-lowering drugs at study entry, 62% did not meet their targets, and despite treatment in the center 1555 of these patients (58%) remained without medication. With regard to national and international guidelines, there is still a need to improve the clinical practice of lowering LDL-C for secondary prevention in high risk patients in Austria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.